KR102110469B1 - 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 - Google Patents

악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 Download PDF

Info

Publication number
KR102110469B1
KR102110469B1 KR1020177037100A KR20177037100A KR102110469B1 KR 102110469 B1 KR102110469 B1 KR 102110469B1 KR 1020177037100 A KR1020177037100 A KR 1020177037100A KR 20177037100 A KR20177037100 A KR 20177037100A KR 102110469 B1 KR102110469 B1 KR 102110469B1
Authority
KR
South Korea
Prior art keywords
pde4d7
expression
prostate cancer
sample
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177037100A
Other languages
English (en)
Korean (ko)
Other versions
KR20180002900A (ko
Inventor
랄프 호프만
마일즈 디. 하우스레이
데이비드 제이. 피. 헨더슨
Original Assignee
코닌클리케 필립스 엔.브이.
더 유니버시티 코트 오브 더 유니버시티 오브 글래스고우
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코닌클리케 필립스 엔.브이., 더 유니버시티 코트 오브 더 유니버시티 오브 글래스고우 filed Critical 코닌클리케 필립스 엔.브이.
Publication of KR20180002900A publication Critical patent/KR20180002900A/ko
Application granted granted Critical
Publication of KR102110469B1 publication Critical patent/KR102110469B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04017—3',5'-Cyclic-nucleotide phosphodiesterase (3.1.4.17)
    • G01N33/57434—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020177037100A 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 Active KR102110469B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09159960 2009-05-12
EP09159960.5 2009-05-12
EP09169739 2009-09-08
EP09169739.1 2009-09-08
PCT/IB2010/052072 WO2010131194A1 (en) 2009-05-12 2010-05-11 Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117029706A Division KR20120036842A (ko) 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7

Publications (2)

Publication Number Publication Date
KR20180002900A KR20180002900A (ko) 2018-01-08
KR102110469B1 true KR102110469B1 (ko) 2020-05-14

Family

ID=42352017

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177037100A Active KR102110469B1 (ko) 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
KR1020117029706A Ceased KR20120036842A (ko) 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117029706A Ceased KR20120036842A (ko) 2009-05-12 2010-05-11 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7

Country Status (9)

Country Link
US (1) US8778621B2 (https=)
EP (1) EP2430190B1 (https=)
JP (4) JP2012526544A (https=)
KR (2) KR102110469B1 (https=)
CN (1) CN102439176B (https=)
BR (1) BRPI1007704A2 (https=)
DK (1) DK2430190T3 (https=)
ES (1) ES2707598T3 (https=)
WO (1) WO2010131194A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700877T3 (es) * 2009-05-12 2019-02-19 Koninklijke Philips Nv Fosfodiesterasa 4D7 como marcador de cáncer de próstata
KR102110469B1 (ko) * 2009-05-12 2020-05-14 코닌클리케 필립스 엔.브이. 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
GB201504763D0 (en) 2015-03-20 2015-05-06 Mironid Ltd Compounds and uses
JP6745820B2 (ja) * 2015-05-29 2020-08-26 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺がん予後判定の方法
JP6743056B2 (ja) * 2015-05-29 2020-08-19 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 前立腺がん予後判定の方法
KR101663675B1 (ko) 2016-07-27 2016-10-07 강성훈 유체 흐름 유도장치
GB201616439D0 (en) 2016-09-28 2016-11-09 Mironid Limited Compounds and uses
KR102546357B1 (ko) * 2016-12-01 2023-06-22 코닌클리케 필립스 엔.브이. 인간 포스포다이에스테라제 4d 변이체 7 발현에 기초한 위험 점수
EP3502280A1 (en) * 2017-12-21 2019-06-26 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables
EP3546598A1 (en) * 2018-03-29 2019-10-02 Koninklijke Philips N.V. Post-surgical risk stratification based on pde4d variant expression, selected according to tmprss2-erg fusion status, and post-surgical clinical variables
GB201805527D0 (en) 2018-04-04 2018-05-16 Mironid Ltd Compounds and their use as pde4 activators
US20210318324A1 (en) 2018-07-05 2021-10-14 The Board Of Regents Of The University Of Oklahoma Gene signatures for cancer characterization and methods of use
EP3636779A1 (en) * 2018-10-11 2020-04-15 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 and dhx9 expression
CN111198270B (zh) * 2018-11-16 2023-04-07 山东泽济生物科技有限公司 一种用于甘油醛-3-磷酸脱氢酶磁微粒化学发光检测试剂盒及其制备方法
EP4608430A1 (en) 2022-10-27 2025-09-03 Koninklijke Philips N.V. Treatment of prostate cancer by promoting pde4d7
EP4360711A1 (en) * 2022-10-27 2024-05-01 Koninklijke Philips N.V. Treatment of prostate cancer by promoting pde4d7
EP4600377A1 (en) 2024-02-12 2025-08-13 Koninklijke Philips N.V. Prediction of an outcome of a subject suffering from a glioma
CN121548649A (zh) 2023-07-18 2026-02-17 皇家飞利浦有限公司 预测患有神经胶质瘤的受试者的结果
EP4603836A1 (en) 2024-02-13 2025-08-20 Koninklijke Philips N.V. Prediction of an outcome of a prostate cancer subject
EP4620461A1 (en) 2024-03-22 2025-09-24 Koninklijke Philips N.V. Treatment of prostate cancer by inhibiting short pde4d isoforms
CN118726352B (zh) * 2024-06-28 2025-11-07 山东大学 启动子元件及其在3-羟基丙酸生物合成中的应用
EP4722388A1 (en) 2024-10-03 2026-04-08 Koninklijke Philips N.V. Prediction of an outcome of a subject suffering from acute myoloid leukemia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261562B1 (en) * 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
HUP0203035A3 (en) * 1998-07-14 2007-12-28 Corixa Corp Compositions and methods for therapy and diagnosis of prostate cancer
EE200300360A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid
IS7221A (is) * 2001-11-15 2004-04-15 Memory Pharmaceuticals Corporation Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
US20030220273A1 (en) * 2002-05-15 2003-11-27 Isis Pharmaceuticals Inc. Antisense modulation of phosphodiesterase 4D expression
WO2004042389A2 (en) 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
CA2542656A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. Qrt-pcr assay system for gene expression profiling
CN101018874A (zh) * 2004-08-13 2007-08-15 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
NZ564223A (en) * 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
AU2007252192B2 (en) * 2006-05-19 2013-10-17 Topigen Pharmaceuticals Inc. Oligonucleotides affecting expression of phosphodiesterases
AU2007271232A1 (en) * 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
US9939441B2 (en) * 2006-07-21 2018-04-10 Epigenomics Ag Methods and nucleic acids for analyses for cellular proliferative disorders
ES2565053T3 (es) * 2007-11-23 2016-03-31 Epigenomics Ag Métodos y ácidos nucleicos para el análisis de metilación de CpG asociada con el desarrollo de trastornos proliferativos de células de próstata
ES2700877T3 (es) * 2009-05-12 2019-02-19 Koninklijke Philips Nv Fosfodiesterasa 4D7 como marcador de cáncer de próstata
KR102110469B1 (ko) * 2009-05-12 2020-05-14 코닌클리케 필립스 엔.브이. 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7

Also Published As

Publication number Publication date
US8778621B2 (en) 2014-07-15
JP2017212973A (ja) 2017-12-07
DK2430190T3 (en) 2019-02-18
CN102439176B (zh) 2018-11-23
EP2430190A1 (en) 2012-03-21
EP2430190B1 (en) 2018-11-21
JP2012526544A (ja) 2012-11-01
JP2019205431A (ja) 2019-12-05
JP2016028245A (ja) 2016-02-25
WO2010131194A1 (en) 2010-11-18
RU2011150264A (ru) 2013-06-20
ES2707598T3 (es) 2019-04-04
JP6246167B2 (ja) 2017-12-13
KR20120036842A (ko) 2012-04-18
JP6588496B2 (ja) 2019-10-09
US20120129788A1 (en) 2012-05-24
KR20180002900A (ko) 2018-01-08
BRPI1007704A2 (pt) 2019-12-03
CN102439176A (zh) 2012-05-02

Similar Documents

Publication Publication Date Title
KR102110469B1 (ko) 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
KR101778036B1 (ko) 전립선암 마커로서의 포스포디에스테라제 4ｄ7
KR20210138587A (ko) 개선된 면역요법을 위한 조합 유전자 표적
CN113853437A (zh) 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
KR20230034198A (ko) 종양 침윤 림프구의 활성화 및 확장 방법
CA2936612A1 (en) Atf6 polymorphisms associated with myocardial infarction, method of detection and uses thereof
KR20210027384A (ko) Scn9a 발현을 조절하기 위한 올리고뉴클레오티드
KR102236784B1 (ko) 성장 호르몬 수용체의 조절인자
KR20220024184A (ko) 대장암의 검출
AU2016376191A1 (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
CN107223159A (zh) 源自特定细胞类型的dna的检测及相关方法
KR20180093902A (ko) 태아와 임신 여성간에 상이하게 메틸화된 디엔에이 영역을 이용한 태아 염색체 이수성의 검출
KR20220025749A (ko) 대장암의 검출
KR20210144822A (ko) Ube3a-ats를 조절하기 위한 화합물 및 방법
KR101621273B1 (ko) 카텝신 ｃ의 용도
CN1423696A (zh) 人类精神分裂症基因
AU2018360287B2 (en) Method for determining the response of a malignant disease to an immunotherapy
CN101151371B (zh) 治疗中的逆转录转座子抑制
CN111344408A (zh) 用于调控fndc3b表达的寡核苷酸
KR20230074214A (ko) 지방간 질환의 치료 방법
KR20190126812A (ko) 질환 진단용 바이오마커
KR20170116009A (ko) 전립선암의 진단을 위한 신규한 rna-바이오마커 시그니처
KR102642320B1 (ko) 항암제에 대한 내성 진단용 조성물
KR101474053B1 (ko) 골다공증 또는 골다공성 골절 발생 위험도 예측용 다형성 마커
KR102477906B1 (ko) 유도만능 줄기세포 분화 특이적 lncRNA, 및 이의 용도

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000